BioCryst Cuts $30M in OpEx, Pivots R&D to External Innovation, Closes Facility
BCRX sits 58% above its 52-week low of $6 on elevated volume (2.2× avg).
Summary
BioCryst announced a major strategic shift, discontinuing internal discovery programs and closing its Birmingham research facility by year-end 2026 to focus on external innovation. This move is expected to reduce 2026 non-GAAP operating expenses by $30 million, lowering guidance from $450-$470 million to $420-$440 million. The company also reported positive pipeline updates, including completed Phase 3 enrollment for navenibart and ongoing Phase 1 dosing for BCX17725, with data expected by Q3 2027 and year-end 2026 respectively. Additionally, a previously disclosed manufacturing delay for ORLADEYO oral pellets has been resolved, with product availability expected in early August. This strategic pivot aims for a more capital-efficient approach to pipeline growth, following a substantial Q1 net loss reported in May.
At the time of this announcement, BCRX was trading at $9.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $6.00 to $10.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.